Slenyto

Description

Slenyto Melatonin is the first and only medicine for the treatment of insomnia, sleeplessness in children with autism spectrum disorders (ASD) and/or Smith-Magenis syndrome (SMS) aged 2 to 18 years.

Slenito is a prolonged-release melatonin mini-tablet, developed specifically for the treatment of insomnia in autistic children, taking into account their specific needs. Insomnia is a disorder of falling asleep and maintaining normal sleep, early awakening or a feeling of dissatisfaction with sleep.

Slenyto Melatonin has been studied in leading pediatric centers in the USA and Europe. The mechanism of action and pharmacokinetics of the drug is that melatonin has a very short half-life (40 minutes). Slenyto is a slow-release melatonin product that uniquely mimics endogenous secretion of the hormone, maintaining elevated melatonin levels throughout the night.

The active ingredient in Slenyto is melatonin, a natural hormone that is normally produced by the pineal gland in the brain. Melatonin helps coordinate the body’s sleep cycle by acting on cells in specific areas of the brain to help you fall asleep. Its levels in the blood typically rise as darkness falls and peak in the middle of the night. Patients with developmental disabilities may produce less melatonin, which can lead to insomnia. Slenito increases melatonin levels in the blood, helping them fall asleep. Because Slenyto releases melatonin slowly over several hours, it mimics the body’s natural melatonin production.

Active ingredient: melatonin

Prescription medicine